Filtered By:
Drug: Amphetamine
Education: Study

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 36 results found since Jan 2013.

Illicit Drug Related Acute Ischemic Stroke, The Impact of Age and Gender (P3.236)
Conclusions: Patient age and sex are poor predictors of illicit drug related acute ischemic stroke. There is underutilization of urine toxicology screening. Acute ischemic stroke standard labs should include urine toxicology screening.Disclosure: Dr. Alhatou has nothing to disclose. Dr. Kirkman has nothing to disclose. Dr. Siddiqui has nothing to disclose. Dr. Alhatou has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Alhatou, M., Kirkman, T., Siddiqui, H., Alhatou, A. Tags: Stroke in the Young Source Type: research

Modafinil for the Improvement of Patient Outcomes Following Traumatic Brain Injury
Conclusion. Modafinil is a central nervous system stimulant with well-established effectiveness in the treatment of narcolepsy and shift-work sleep disorder. There is conflicting evidence about the benefits of modafinil in the treatment of fatigue and EDS secondary to TBI. One randomized, controlled study states that modafinil does not significantly improve patient wakefulness, while another concludes that modafinil corrects EDS but not fatigue. An observational study provides evidence that modafinil increases alertness in fatigued patients with past medical history of brainstem diencephalic stroke or multiple sclerosis. ...
Source: Innovations in Clinical Neuroscience - April 1, 2018 Category: Neuroscience Authors: ICNS Online Editor Tags: Current Issue Review excessive daytime sleep fatigue head injury modafinil stroke TBI traumatic brain injury Source Type: research

Risk of stroke in prescription and other amphetamine ‐type stimulants use: A systematic review
Conclusions. This is the first systematic review on ATS and stroke. Limited epidemiological evidence suggests that ATS use increases stroke risk. Possible disparities in ATS effect across stroke type and higher effect in women deserve further clarification. Studies on non‐medical ATS use should be a priority. [Indave BI, Sordo L, Bravo MJ, Sarasa‐Renedo A, Fernández‐Balbuena S, De la Fuente L, Sonego M, Barrio G. Risk of stroke in prescription and other amphetamine‐type stimulants use: A systematic review. Drug Alcohol Rev 2017;00:000–000]
Source: Drug and Alcohol Review - May 8, 2017 Category: Addiction Authors: Blanca Iciar Indave, Luis Sordo, Mar ía José Bravo, Ana Sarasa‐Renedo, Sonia Fernández‐Balbuena, Luis De la Fuente, Michela Sonego, Gregorio Barrio Tags: Comprehensive Review Source Type: research

The efficacy and safety of pharmacological treatments for post-stroke aphasia.
Conclusions Current evidence suggests that drugs can improve the prognosis of post-stroke aphasia, such as donepezil, memantine. Donepezil has a significant effect in improving the ability of auditory comprehension, naming, repetition and oral expression. Memantine has a significant effect in improving the ability of naming, spontaneous speech and repetition. Bromocriptine showed no significant improvement in the treatment of aphasia after stroke. The trial for galantamine, amphetamine and levodopa in the treatment of aphasia after stroke is limited and inconclusive. PMID: 29984673 [PubMed - as supplied by publisher]
Source: CNS and Neurological Disorders Drug Targets - July 6, 2018 Category: Drugs & Pharmacology Authors: Zhang X, Shu B, Zhang D, Huang L, Fu Q, Du G Tags: CNS Neurol Disord Drug Targets Source Type: research

Pharmacotherapy and motor recovery after stroke.
Authors: Viale L, Catoira NP, Di Girolamo G, González CD Abstract INTRODUCTION: Stroke is one of the most prevalent neurological diseases worldwide, especially among the elderly population. There are various mechanisms that enhance motor recovery after a stroke. In clinical practice, we have the opportunity to enhance plasticity by designing specific rehabilitation programs. Areas covered: There are a variety of drugs commonly administered to people after the acute phase of a stroke. These drugs may modify motor performance. Herein reviewed is the evidence concerning motor enhancement or decline in stroke patients, p...
Source: Expert Review of Neurotherapeutics - November 11, 2017 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Neurobiology of amphetamine use in stroke recovery combined with rehabilitative training and brain stimulation
CNS Neurol Disord Drug Targets. 2022 May 12. doi: 10.2174/1871527321666220512155811. Online ahead of print.ABSTRACTStroke is a physiological disorder involving a prolonged local interruption of cerebral blood flow. It leads to massive neuronal death and causes short-term or long-lasting functional impairment. Most stroke victims regain some neural function weeks or months following a stroke, but this recovery can plateau six months or more after the injury. The goal of stroke therapy is the rehabilitation of functional capabilities, especially those affecting the patient's autonomy and quality of life. Recent clinical and ...
Source: CNS and Neurological Disorders Drug Targets - May 13, 2022 Category: Drugs & Pharmacology Authors: Mohammad Uzair Muhammad Arshad Turki Abualait Zeyad T Al-Harbi Talal M Al-Harbi Reem Bunyan Fahad Abida Arshad Woo Kyoung Yoo Shahid Bashir Source Type: research

Intracerebral Hemorrhage Associated with Oral Phenylephrine Use: A Case Report and Review of the Literature
Conclusions: It is scientifically plausible that phenylephrine may cause strokes, consistent with the pharmacologic properties and adverse event profiles of similar amphetamine-like sympathomimetics. As RCVS has been well described in association with over-the-counter sympathomimetics, a likely, although not definitive, causal relationship between phenylephrine and ICH is proposed.
Source: Journal of Stroke and Cerebrovascular Diseases - August 25, 2014 Category: Neurology Authors: Brian E. Tark, Steven R. Messe, Clotilde Balucani, Steven R. Levine Tags: Original Articles Source Type: research

Amphetamine and post-stroke rehabilitation: indications and controversies.
Abstract There is robust evidence for amphetamine (AMPH) facilitated recovery from behavioral deficits in animal models of stroke. Following experimental lesions, numerous studies of motor, somatosensory and vision recovery show AMPH accelerates the rate of recovery when paired with relevant behavioral experience. While the experimental literature continues to mount for an AMPH effect, the translation to clinical studies has been far less clear. This is due in part to the inherent difficulty of extrapolating results in animals to humans; however, there is much controversy regarding how the basic science data is in...
Source: European Journal of Physical and Rehabilitation Medicine - April 5, 2013 Category: Rehabilitation Authors: Walker-Batson D Tags: Eur J Phys Rehabil Med Source Type: research

Preworkout Supplement Induced Hemorrhagic Stroke: A Case Report
Abstract: Hemorrhagic stroke is a catastrophic cause of both long-term morbidity and mortality. Many risk factors for development of these strokes are in fact preventable or modifiable in nature. This case report outlines an incident involving a previously healthy 24-year-old man with no apparent risk factors apart from consumption of preworkout supplementation who developed a hemorrhagic stroke. The supplements that this particular patient was consuming included various potential causative agents—with the most significant being Dendrobium extract, which contains compound B-phenylethylamine, a precursor in the amphet...
Source: Clinical Journal of Sport Medicine - November 1, 2021 Category: Sports Medicine Tags: Case Report Source Type: research

The Amphetamine-Enhanced Stroke Recovery (AESR) Trial: Primary Part 1 Results (S45.003)
CONCLUSIONS:The studied treatment regimen was safe. Primary results will be presented.Study Supported by:NIH-NS39934Disclosure: Dr. Goldstein has received personal compensation for activities with Pfizer Inc. Dr. Goldstein has received royalty payments from Up To Date, Henry Stewart Talks, and Quantia. Dr. Goldstein has received research support from AGA. Dr. Rabadi has nothing to disclose. Dr. Reding has received personal compensation for activities with Acorda Therapeutics as a consultant. Dr. Lennihan has nothing to disclose. Dr. Good has received personal compensation for activities with Allergan, Inc. Dr. Good has rec...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Goldstein, L., Rabadi, M., Reding, M., Lennihan, L., Good, D., Dromerick, A., Pura, J., Samsa, G. Tags: Cerebrovascular Disease and Interventional Neurology: Rehabilitation, Recovery, and Complications Source Type: research

Amphetamine and other pharmacological agents in human and animal studies of recovery from stroke
Publication date: Available online 18 April 2015 Source:Progress in Neuro-Psychopharmacology and Biological Psychiatry Author(s): D. Walker-Batson , J. Mehta , P. Smith , M. Johnson Neuromodulation with pharmacological agents, including drugs of abuse such as amphetamine, when paired with behavioral experience, has been shown to positively modify outcomes in animal models of stroke. A number of clinical studies have tested the efficacy of a variety of drugs to enhance recovery of language deficit post-stroke. The purpose of this paper is to: (1) present pertinent animal studies supporting the use of dextro-amphetamine su...
Source: Progress in Neuro Psychopharmacology and Biological Psychiatry - April 28, 2015 Category: Psychiatry Source Type: research

Stimulants May Pose Short-Term Cardiovascular Risks in Older Adults
Older adults prescribed stimulant medications appear to be at an elevated risk of cardiovascular problems in the first 30 days after beginning the treatment, according to astudy published today inJAMA Network Open. However, these risks decrease over time, with no evidence of increased cardiovascular risk at six months and one year after initiating treatment.“Although stimulants are most commonly used among children and youth for the treatment of attention-deficit/hyperactivity disorder (ADHD), an increase in stimulant use among older adults in recent years has been observed,” wrote Mina Tadrous, PharmD., Ph.D., of the ...
Source: Psychiatr News - October 25, 2021 Category: Psychiatry Tags: cardiovascular problems heart attack JAMA Network Open off-label use older adults stimulants stroke transient ischemic attack ventricular arrhythmia Source Type: research